The Effect Of Ranolazine Treatment Administered Before Coronary Artery Bypass Surgery On Perioperative Myocardial Damage In Patients With Stable Angina Pectoris

Stabil Angina Pektorsli Hastalarda Koroner Arter Baypas Cerrahisi Öncesi Ranolazin Tedavisinin Peroperatif Miyokard Hasarı Üzerine Etkisi

**Abstract**

**Objective:** Ranolazine is a piperazine derivative that has been approved as an antianginal agent. It is primarily used as a second-line antianginal agent in stable coronary artery disease. The study was designed considering that the active ingredient ranolazine, which has antiischemic effects through ischemic sodium channels, can reduce ischemia in the perioperative period and reduce the frequency of perioperative myocardial infarction.

**Methods:** The study included patients with stable angina pectoris who underwent coronary angiography between January 1, 2015 and June 30, 2016 at Koşuyolu Training and Research Hospital and who were diagnosed with multi-vessel disease or LMCA disease, and then for whom the joint council of Cardiology-Cardiovascular Surgery made a decision in favor of coronary artery bypass grafting.

**Results:** The mean age was 61.2 ± 8.6 years in the ranolazine group, while the mean age of the patients receiving standard therapy was 57.9 ± 8.8 years (p = 0.073). The EuroSCOREs of the patients before the operation which were used to predict intraoperative mortality were similar. Mean troponin value of Group 1 patients at 0 hour was 1.70 (1.13-2.77), while mean troponin value of the patients in Group 2 at 0 hour was 2.76 (1.69-6.20) (p=0.01).

**Conclusion:** In the present study, the immediate postoperative troponin 0 value was found to be lower in the ranolazine group. There was no statistical difference in terms of troponin values measured at 12 and 24 hours. In this study, we showed that early myocardial damage was significantly reduced with ranolazine treatment.

**Keywords:** bypass, ranolazine, myocardial damage

**Correspondence:** Mehmet Fatih Yılmaz, Dr. Siyami Ersek Göğüs Kalp Ve Damar Cerrahisi Eğitim Araştırma Hastanesi, İstanbul, Türkiye. E-mail: fhylmz1987@gmail.com

**CITATION:**

Kocaeli Medical Journal 2021 https://kocaelimj.org

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial International License.
INTRODUCTION

Stable angina pectoris (SAP) is a chronic disease that has a significant impact on mortality and quality of life. Angina pectoris is the most common clinical manifestation of ischemic heart disease. (1,2)

Ischemia-reperfusion injury is one of the most important problems in cardiac surgery and may cause postoperative malignant arrhythmia, perioperative myocardial infarction, and decreased cardiac output. Despite the scientific developments at the cellular level and the use of cardioprotective methods, it has not yet been possible to completely prevent reperfusion injury. (3)

The function of cardiac troponin in myocardial contraction is to regulate the calcium-related interaction of actin and myosin. Therefore, determination of cardiac troponin is a very important tool, for example in the diagnosis of acute myocardial infarction and myocardial cell necrosis. (4)

Ranolazine is a piperazine derivative that has been approved as an antianginal agent. It is primarily used as a second-line antianginal agent in stable coronary artery disease. Ranolazine acts by blocking the late sodium channels (INa) and prevents the elevation of cytosolic calcium. It reduces myocardial wall tension and improves coronary blood flow. (5)

The study was designed considering that the active ingredient ranolazine, which has antiischemic effects through ischemic sodium channels, can reduce ischemia in the perioperative period and reduce the frequency of perioperative myocardial damage. Which was evaluated previously and shown to reduce the frequency of perioperative myocardial damage after percutaneous coronary stent placement.

The aim of this study was to examine the postoperative effects of preoperative administration of ranolazine treatment on myocardial damage.

MATERIALS AND METHOD

The study included patients with stable angina pectoris who underwent coronary angiography (CAG) between January 1, 2015 and June 30, 2016 in the Department of Cardiology at Kartal Koşuyolu Yüksek İhtisas Training and Research Hospital and who were diagnosed with multi-vessel disease or LMCA disease, and then for whom the joint council of Cardiology-Cardiovascular Surgery made a decision in favor of coronary artery bypass grafting (CABG). Patients who underwent a surgical procedure other than CABG (mitral valve repair, mitral valve replacement, aortic valve replacement, etc.) were excluded from the study. The necessary permission was obtained from the ethics committee of our hospital for the study protocol.

Age, gender, risk factors for coronary artery disease (hypertension, diabetes, hyperlipidemia, smoking, and family history) of all patients included in the study were recorded. Hypertension was defined as having been previously diagnosed and receiving antihypertensive treatment, diabetes as receiving oral anti-diabetic or insulin therapy, and dyslipidemia as receiving lipid-lowering treatment at presentation. Syntax scores, EuroSCORE II and LV ejection fraction (echocardiographic), body weight, and creatinine values of all patients were recorded.

Criteria for exclusion from the study:

Patients with a previous history of revascularization, patients with ejection fraction less than 40% (as it may cause high troponin), patients with preoperative renal failure (creatinine >1.3 mg/dl or creatinine clearance <80 ml/min), patients with long QTc on ECG (>440 ms in men), (women >460 ms), patients with myocardial infarction (MI) or unstable angina pectoris (USAP) in the last 3 months, and patients with elevated troponin values for any reason were excluded from the study.

Patients who underwent coronary angiography (CAG) with a diagnosis of stable angina pectoris and for whom a decision was made in favor of
surgery were included in the study considering the exclusion criteria. Our study was designed retrospectively. Between 2015 and 2016, patients who were scheduled for CABG and who were using ranolazine were screened retrospectively. Troponin was measured at 0, 12, and 24 hours postoperatively. ECG monitoring was performed daily.

STATISTICAL ANALYSIS

Mean ± standard deviation and median (maximum-minimum) values were used for continuous variables, and percentage was used for categorical variables. Normal distribution was tested with one-sample Kolmogorov-Smirnov test. Unpaired t-test was used to test the difference in terms of the normally distributed continuous variables between the patient and control groups. In continuous variables that do not conform to the normal distribution, Mann–Whitney U test was used to test the difference between two groups. Pearson Chi-square test was used to test categorical variables.

A p-value of <0.05 was considered significant for all tests. Statistical Package for the Social Sciences (SPSS version 11.0, SPSS Inc., Chicago, IL, USA) was used.

RESULTS

The mean age was 61.2 ± 8.6 years in the ranolazine group, while the mean age of the patients receiving standard therapy was 57.9 ± 8.8 years (p = 0.073).

While the rate of diabetic patients in group 1 was 52.8% and 38% in the second group (p = 0.077) While the rate of smoking patients in group 1 was 45.7% and 54% in group 2 (p = 0.239). The EuroSCOREs of the patients before the operation which were used to predict intraoperative mortality were similar.

The Syntax scores of the patients calculated by considering the morphological characteristics of all lesions on CAG were similar.

In group 1, the rate of single CABG was 5.7%, double CABG was 27.14%, triple CABG was 50%, quadruple CABG was 15.7%, and quintuple CABG was 1.42%; while in group 2, the rate of single CABG was 6%, double CABG was 28%, triple CABG was 42%, quadruple CABG was 24%, and quintuple CABG was 0%. (Table 1)

| Table 1. Clinical and Demographic Characteristics of the Patients |
|---------------------------------------------------------------|
| **Group 1 N:70** | **Group 2 N:50** | **p** |
| --- | --- | --- |
| **Age** | 61.2 ± 8.6 | 57.9 ± 8.8 | 0.073 |
| **Height** | 168.4 ± 7.0 | 169.8 ± 6.6 | 0.274 |
| **Body Weight** | 79.5 ± 11.0 | 80.2 ± 7.5 | 0.536 |
| **BMI** | 27.9 ± 3.3 | 27.7 ± 2.0 | 0.759 |
| **Ejection Fraction** | 58.5 ± 7.2 | 58.6 ± 7.8 | 0.714 |
| **DM n(%)** | 37 (52.8%) | 19 (38%) | 0.077 |
| **HT n(%)** | 46 (65.7%) | 30 (60%) | 0.326 |
| **HL n(%)** | 47 (67.1%) | 30 (60%) | 0.270 |
| **Smoking n(%)** | 32 (45.7%) | 27 (54%) | 0.239 |
| **Hemoglobin** | 13.54 ± 1.45 | 13.47 ± 2.3 | 0.639 |
| **Urea** | 37.19 ± 9.8 | 36.09 ± 8.0 | 0.727 |
| **Creatinine** | 0.82 ± 0.1 | 0.82 ± 0.1 | 1.0 |
| **TSH** | 1.69 ± 1.2 | 1.55 ± 0.9 | 0.933 |
| **Euroscore** | 1.19 ± 0.4 | 1.07 ± 0.3 | 0.051 |
| **Syntax Score** | 18.2 ± 2.7 | 18.9 ± 3.0 | 0.148 |
| **Number of grafts n(%)** | | | 0.239 |
| 1G 4 (5.7%) | 2G 3 (6%) |
| 2G 19 (27.14%) | 2G 14 (28%) |
| 3G 35 (50%) | 3G 21 (42%) |
| 4G 11 (15.7%) | 4G 12 (24%) |
| 5G 1 (1.42%) | 5G 0 (0%) |
Mean EF value of the patients in Group 1 was 58.5% (65-40), and mean EF was 58.6 (65-45) in Group 2 (p = 0.714). Perfusion time and aortic clamping times of both groups were similar (Table 2). In addition, the lowest temperature and the lowest pH value measured during the operation were also similar. (Table 2)

Mean troponin value of Group 1 patients at 0 hour was 2.52 ± 2.38, while mean troponin value of the patients in Group 2 at 0 hour was 7.95 ± 17.13 (p = 0.008).

The clinical and demographic characteristics of the patients in both groups are shown in Tables 1 and surgical features and troponin values are shown in Table 2.

| Table 2. Table 2: Clinical and Demographic Characteristics of the Patients |
|-------------------------------------------------|---------|---------|----------|
| Perfusion time                                  | 84.94 ± 22.6 | 81.9 ± 19.7 | 0.657    |
| Aortic clamping time                           | 53.51 ± 14.7 | 56.16 ± 15.4 | 0.313    |
| Temperature                                    | 30.3 ± 1.0 | 30.1 ± 0.6 | 0.688    |
| Ph the patients                                | 7.33 ± 0.4 | 7.32 ± 0.6 | 0.157    |
| Troponin value at 0 h                          | 1.70 (1.13-2.77) | 2.76(1.69-6.20) | 0.01    |
| Troponin value at 12 h                         | 1.59(0.90-2.81) | 1.76(1.08-3.28) | 0.43    |
| Troponin value at 24 h                         | 0.71(0.49-1.44) | 1.06(0.65-1.67) | 0.12    |

DISCUSSION

In the present study, the immediate postoperative troponin 0 value was found to be lower in the ranolazine group. There was no statistical difference in terms of troponin values measured at 12 and 24 hours. In this study, we showed that early myocardial damage was significantly reduced with ranolazine treatment.

CABG is a basic and effective surgical method for coronary artery disease. [6] Ischemia reperfusion injury during and after CABG can lead to reversible and irreversible myocardial damage (7). Although various methods have been developed to reduce this adverse effect on the myocardial tissue, cardiac dysfunction is still common. (8)

Methods of myocardial preservation play a key role during CABG. (9)

Ranolazine acts by selective inhibition of late Na channels by decreasing intracellular calcium load and diastolic tension secondary to this (10). The most important feature of this drug is that it acts only on ischemic cells rather than normal myocytes at therapeutic doses. In addition, it does not have any effect on blood pressure and heart rate, which is also important.

The efficacy of ranolazine in chronic stable patients has been demonstrated in many randomized clinical trials. It was shown that the total exercise time and the time to angina onset significantly increased compared with placebo when ranolazine was given to the patients who participated in the MARISA study, (11). In the CARISA study, ranolazine significantly increased exercise time and time to anginal pain, regardless of the changes in blood pressure and heart rate and the treatment method used in the background, and decreased the weekly number of anginal attacks in patients with chronic stable angina (12). On the other hand, in the ERICA study, it was investigated whether addition of ranolazine to amiodipine treatment led to any additional benefits (13). Ranolazine was found to significantly reduce the prevalence of angina and nitrate consumption, and it was found to be equally effective in male and female patients, in patients who received and did not receive long-acting nitrates, and in those who were over or below 65 years of age.

It has been shown in multi-center randomized studies that ranolazine improves angina symptoms and exercise time in patients with known coronary artery disease. (14-16) The first study of ranolazine on periprocedural MI was conducted in 70 patients who underwent elective percutaneous coronary intervention (PCI) with the diagnosis of stable angina pectoris and ranolazine group has lower periprocedural MI than other group (17) It has been reported that the pleotropic-antiangiinal effect of ranolazine may improve endothelial dysfunction, decrease the inflammatory process, and decrease post-PCI microembolism by reducing alpha 1 activity in vascular tone. (18-19)
Post CABG miyocardial damage may be originated from insufficient protection of the myocardium during the period when the aorta is cross-clamped, incomplete surgical revascularization, vasospasm, atheromatous embolism from a previous bypass graft or aorta, air embolism, or thrombosis of a native artery or a new graft (20,21).

In the present study, the efficacy of ranolazine was investigated in patients who underwent elective CABG with the diagnosis of SAP, based on a previous study showing the positive effects of ranolozone on post MI in the PCI group. In our study equal ischemia time and similar preoperative angiographic atherosclerosis grades between groups eliminated the difference in terms of ischemia-necrosis. The difference in early troponin values in the post period has shown that ranolazine is beneficial in terms of perioperative myocardial damage in the early period. This result may be originated by ranolazine late sodium channel blocking effect and the decreased intracellular calcium level by this mechanism ischemia and necrosis may be reduced, but this difference disappeared in the subsequent period after revascularization of ischemic myocardial tissue. Ivabradine which can be used as an antianginal drug showed positive results on myocardial damage in the post-CABG study and this effect was attributed to the decreased heart rate. (22) The fact that ranolazine does not affect heart rate and blood pressure may explain the absence of a decrease in troponin levels in the postoperative long term results. The early difference may be attributed to the effect of ranolazine on ischemic tissue. There is a need for larger randomized trials regarding this subject.

CONCLUSION

Our study demonstrated that ranolazin has protective effect in early period until revascularization for myocardial damage, for patients who could not full revascularited by CABG ranolazine treatment should be keep in mind for protection of myocardial damage.

LIMITATIONS

The main limitations of the present study were that it was not single-centered and randomized, and the number of patients was low. In addition, involving different surgical teams was another limitation. Another limitation was that the newly developing wall motion abnormality and occlusion of native or graft artery were not demonstrated by an invasive or a non-invasive method for the diagnosis of post-operative MI. In addition, the CK-MB value was not analyzed in the laboratory of our hospital, which was also a limitation because of our study retrospective design.

ACKNOWLEDGEMENTS

Conflict of Interest

The authors declare that they have no conflict of interests regarding content of this article.

Financial Support

The Authors report no financial support regarding content of this article.

Ethical Declaration

Ethical approval was obtained from the Recep Tayyip Erdoğan University, Clinical Research Ethics Committee with date 14.04.2019 and number 2019-57, and Helsinki Declaration rules were followed to conduct this study.

Informed Consent

This is a retrospective study.

REFERENCES

1. Task Force Members, Montalescot G, Sechtem U, Achenbach S, et al 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.

2. Scarborough P, Bhatnagar P, Wickramasinghe K, Smolina K, Mitchell C, Rayner M. Coronary heart disease statistics 2010. British Heart Foundation 2010.
3. Harpey C, Clauser P, Labid C, Freyria JL, Poirier JP. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev 1988;6:292-312.

4. Christenson, R.H., Duh, S.H., Newby, L.K., Ohman, E.M., Califf, R.M., Granger, C.B., Peck, S., Pieper, K.S., Armstrong, P.W., Katus, H.A., Topol, E.J., 1998. Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators Clin. Chem. 44, 494–501.

5. Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 2008;44:954-67.

6. Varnauskas E. Twelve-year follow-up of survival in the randomized European coronary surgery study. N Engl J Med 1988;319:332-7.

7. Hoffman JW Jr, Gilbert TB, Poston RS, Silldorff EP. Reperfusion injury: Etiology, mechanisms, and therapies. J Extra Corpor Technol 2004;36:391-411.

8. De Vecchi, E, Pala MG, Di Credico G, Agape V, Paolini G, Bonini PA. Relation between left ventricular function and oxidative stress in patients undergoing bypass surgery. Heart 1998;79:242-7.

9. Zhang N, Lei J, Liu Q, Huang W, Xiao H, Han Lei H. The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: A systematic review and meta-analysis. Cardiology 2015;131:86-96.

10. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45:469–91.

11. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J et al; MARISA Investigators. Antiischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82.

12. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch Jet al. Effect of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-16.

13. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) Trial. J Am Coll Cardiol 2006;48:566-75.

14. Chaitman BR, Skettino SL, Parker JO, et al, for MARISA investigators. Anti-ischemic effects and long-term survival during ranolazinemonotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82.

15. Stone PH, Gratsiansky NA, Blokhin A, et al, ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566-75.

16. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al, MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007;297:1775-83.

17. Pelliccia F, Pascrei V, Marazzi G, Rosano G, Greco C, Gaudio C. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention. Am Heart J. 2012 Jun;163(6):1019-23. https://doi.org/10.1016/j.ahj.2012.03.018
18. Deshmukh SH, Patel SR, Pinassi E, et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis 2009;20:343-7.

19. Nieminen T, Tavares CA, Pegler JR, et al. Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model. Circ Cardiovasc Interv 2011;4:481-7.

20. Jain U. Myocardial ischemia after cardiopulmonary bypass. J Card Surg. 1995;10:520.

21. Phillips DF, Proudfit W, Lim J, et al. Perioperative myocardial infarction: Angiographic correlation. Am J Cardiol 1977;39:269.

22. Lo Sapio P, Gensini GF, Bevilacqua S, Chiti E, Paperetti L, Pratesi C, Romano SM. The role of ivabradine in the incidence of perioperative coronary complications in patients undergoing vascular surgery. Int J Cardiol. 2013 Oct 9;168(4):4352-3